News

Public · Published

Buy Rainbow Childrens Medicare; target of Rs 1650: Prabhudas Lilladher

Prabhudas Lilladher maintained a Buy rating on Rainbow Childrens Medicare with a revised target price of Rs 1,650 per share. The company reported second-quarter EBITDA of INR 1.7bn, up 14% from a year earlier, and added 50% more beds over two years.

Published:

Updated:

What happened

Prabhudas Lilladher maintained a Buy rating on Rainbow Childrens Medicare with a revised target price of Rs 1,650 per share. The company reported second-quarter EBITDA of INR 1.7bn, up 14% from a year earlier, and added 50% more beds over two years.

Confirmed

Global impact / market context

A higher target price means the broker expects the share price to rise toward that level. Rainbow's added beds should lift revenue as they fill up, while focused marketing and new doctor hiring raise costs first. The broker cut its EBITDA forecasts by 4-6%, meaning slightly lower expected operating profit than before.

Analyst inference

Rainbow is described as India's only integrated multi-specialty pediatric hospital chain, using an asset-light hub-and-spoke model: smaller clinics feed patients into larger hub hospitals. That model supports strong free cash flow, which is cash left after spending, plus a net cash balance sheet, meaning cash exceeds debt.

Analyst inference

What to watch

  1. Rainbow concluded its current expansion cycle after adding 50% bed capacity over the past two years, so watch how quickly these new beds fill and contribute to revenue. Confirmed
  2. The broker expects profitability to improve from FY27, with about 19% EBITDA compound annual growth over FY26-29E, which means yearly profit growth, versus 13% over FY24-26. Proposed
  3. Watch whether focused marketing and new clinical hiring pay off in coming quarters, and whether strategic expansion across South India core markets supports sustainable growth without pressuring margins. Analyst inference

Evidence

  • Original source link unavailable